PF-Atlas › Clinical Trials › NCT00486837
Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
Alpha1-Proteinase Inhibitor · Phase 2
Registry ID
NCT00486837
Phase
Phase 2
Status
Completed
Drug / intervention
Alpha1-Proteinase Inhibitor (Human)
Sponsor
Grifols Therapeutics LLC
Start
2003-12
About this trial
Alpha1-Proteinase Inhibitor is evaluated in NCT00486837, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Grifols Therapeutics LLC. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00486837 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.